Article
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2018
Paoletti Costanza, Schiavon Gaia, Dolce Emily M, Darga Elizabeth P, Carr T Hedley, Geradts Joseph, Hoch Matthias, Klinowska Teresa, Lindemann Justin, Marshall Gayle, Morgan Shethah, Patel Parul, Rowlands Vicky, Sathiyayogan Nitharsan, Aung Kimberly, Hamilton Erika, Patel Manish, Armstrong Anne, Jhaveri Komal, Im Seock-Ah, Iqbal Nadia, Butt Fouziah, Dive Caroline, Harrington Elizabeth A, Barrett J Carl, Baird Richard, Hayes Daniel F
Abstract excerpt
PURPOSE: Common resistance mechanisms to endocrine therapy (ET) in estrogen receptor (ER)-positive metastatic breast cancers include, among others, ER loss and acquired activating mutations in the ligand-binding domain of the ER gene (ESR1LBDm). ESR1 mutational mediated resistance may be overcome by selective ER degraders (SERD). During the first-in-human study of oral SERD AZD9496, early changes in circulating...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.